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Abstract
Mature dendritic cells (DCs) represent cellular adjuvants for optimal antigen presentation in cancer vaccines. Recently, 
a combination of prostaglandin  E2  (PGE2) with Toll-like receptor agonists (TLR-P) was proposed as a new standard to 
generate superior cytokine-producing DCs with high migratory capacity. Here, we compare TLR-P DCs with conventional 
DCs matured only with the proinflammatory cytokines TNFα and IL-1ß (CDCs), focussing on the interaction of resulting 
DCs with  CD8+ T-cells. TLR-P matured DCs showed elevated expression of activation markers such as CD80 and CD83 
compared to CDCs, together with a significantly higher migration capacity. Secretion of IL-6, IL-8, IL-10, and IL-12 was 
highest after 16 h in TLR-P DCs, and only TLR-P DCs secreted active IL-12p70. TLR-P DCs as well as CDCs successfully 
primed multifunctional  CD8+ T-cells from naïve precursors specific for the peptide antigens Melan-A, NLGN4X, and PTP 
with comparable priming efficacy and T-cell receptor avidity.  CD8+ T-cells primed by TLR-P DCs showed significantly 
elevated expression of the integrin VLA-4 and a trend for higher T-cell numbers after expansion. In contrast, TLR-P DCs 
displayed a substantially reduced capability to cross-present CMVpp65 protein antigen to pp65-specific T cells, an effect 
that was dose-dependent on  PGE2 during DC maturation and reproducible with several responder T-cell lines. In conclu-
sion, TLR-P matured DCs might be optimal presenters of antigens not requiring processing such as short peptides. However, 
 PGE2 seems less favorable for maturation of DCs intended to process and cross-present more complex vaccine antigens such 
as lysates, proteins or long peptides.
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matured with TNFα, IL-1ß)
COX-2  Cyclooxygenase 2
CMV  Cytomegalo virus
DC  Dendritic cell
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GMP  Good manufacturing practice
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MFI  Mean fluorescence index
TLR-P-DC  Monocyte-derived DC, matured with 
TLR3 + 7/8 agonists and PGE2
MDSC  Myeloid-derived suppressor cells
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TCR  T-cell receptor
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PTP  Tyrosine-protein phosphatase non-receptor
VLA-4  Very late antigen-4 (α4ß1 integrin
Introduction
Cancer vaccines aim at inducing T-cell responses against 
particular antigens which segregate tumor cells from non-
malignant cells within an organism. Candidate antigens 
for such a delicate distinction are either derived from non-
synonymous mutations in tumor proteins (e.g. neo-antigenic 
peptides) or tumor-associated antigens (i.e. non-mutated 
proteins expressed exclusively or aberrantly in tumor cells). 
Vaccines can contain antigen as tumor lysate, proteins, 
DNA/RNA, or long peptides. These formats offer the advan-
tage of presentation on both HLA class I and II molecules 
after intracellular processing to promote simultaneous  CD4+ 
and  CD8+ T-cell responses [1]. Other groups favor mixes 
of short HLA class I peptides, which bind to membrane-
bound HLA class I molecules, do not require processing, 
and can be synthesized custom tailored for each patient [2]. 
An inherent problem with cancer antigens is that TCRs with 
a specificity for tumor-associated peptides have at least one 
log lower affinity for their target peptide-MHC complex than 
TCRs with viral specificity [3]. To compensate for this and 
yet allow appropriate sensing of the applied antigen by the 
immune system, an optimal presentation of cancer vaccine 
antigens is mandatory. Chemical adjuvants commonly used 
in vaccination trials such as alum salts, Montanide, or GM-
CSF suffer from substantial shortcomings such as promoting 
Th2 responses, inducing dysfunctional T-cells or myeloid-
derived suppressor cells [2, 4, 5], making the search for bet-
ter adjuvants a major goal in cancer vaccine development.
Naturally occurring professional antigen-presenting cells 
such as DCs potentially might overcome many of the draw-
backs of synthetic adjuvants. DCs actively exert important 
vaccine promoting functions in vivo, such as antigen trans-
port via targeted migration into secondary lymphoid organs, 
longevity, and phenotype stability for at least 3–4 days, 
cross-presentation of ingested antigen to  CD8+ T-cells, and 
secretion of appropriate cytokines at the DC:T synapse, ulti-
mately leading to successful priming of naïve T-cells and 
memory formation. However, as DCs are a highly versatile 
cell population, there is no consensus on how to prepare 
DC precursors for their role in a cancer vaccine. Histori-
cally, conventional dendritic cells (CDCs) have been gener-
ated from monocyte precursors by inducing differentiation 
towards an immature DC state with IL-4 and GM-CSF and 
after antigen loading in the phagocytic stage, maturation 
with a cytokine-based cocktail containing TNFα, IL-1ß, 
IL-6 and prostaglandin  E2  (PGE2) [6]. However, evidence 
emerged that some essential functions (e.g. migratory and 
cytokine secretion capabilities) might be mutually exclusive 
in monocyte-derived DCs and that  PGE2 is a decisive switch 
in that process [7]. Production of IL-12p70, an important 
cytokine influencing the properties of  CD8+ T- and NK-
cells, was found to be impaired by  PGE2 [8] and presence of 
 PGE2 during iDC maturation resulted in an IL-10 depend-
ent abrogation of antigen-specific T-cell proliferation [9]. 
Furthermore,  PGE2 can trigger a COX-2-driven positive 
feedback loop in monocytes and redirect their differentiation 
into MDSCs [10]. Altogether, these data led to removal of 
 PGE2 from DC maturation cocktails by several groups [11]. 
In our own brain tumor vaccination program, we have used 
TNFα and IL-1ß as maturing agents so far and validated this 
combination as the standard for generation of clinical-grade 
DCs under GMP [12, 13].
TLRs are innate receptors on antigen-presenting cells 
sensing pathogen-associated molecular patterns in antimi-
crobial defense. Their triggering induces potent activation of 
DCs, harnessing them with competence for optimal antigen 
transport and T-cell activation. Combinatorial triggering of 
the TLR3/4 and TLR7/8/9 subgroups was shown to syner-
gistically activate a type-1 polarizing program for T helper 
cells together with high IL-12/-23 production and a specific 
transcriptome in DCs [14] through MyD88-dependent and 
-independent pathways [15]. TLR-matured DCs exclusively 
activated  CD8+ T-cells with granzyme B/chemokine recep-
tor (CCR-)5 expression and CTL activity [16]. These find-
ings were rapidly translated into DC manufacturing proto-
cols in the cancer vaccine setting. PolyI:C, a TLR3 agonist 
which mimics viral double stranded RNA (dsRNA), was 
added to a cytokine-based DC maturation cocktail, result-
ing in increased IL-12p70 production by DCs and a supe-
rior induction of melanoma-specific CTL responses [17]. 
Enhanced stimulation of tumor-specific T-cells was achieved 
when polyI:C and R848 (Resiquimod, a synthetic low-
molecular-weight agonist of TLR7/8) were combined with 
LPS, the classical TLR4-ligand [18]. Furthermore, research-
ers were interested to analyze whether the combined use 
of TLR-agonists and  PGE2 was able to generate DCs with 
both cytokine-secreting and migratory capabilities. Boullard 
et al. investigated the effect of adding  PGE2 to polyI:C and 
R848 on DC phenotype, migratory capacity, IL-12p70 pro-
duction, and T-cell cytokine secretion. They concluded that 
the combination of TLR3&7/8 agonists with  PGE2 (TLR-
P) results in DCs with improved migratory capacity and 
maintained IL-12p70 production [19]. However, important 
DC functions such as DC:T interactions were not assessed 
in that report. Here, we compare our extensively validated 
TNFα/IL-1ß cytokine combination, already used in clini-
cal trials, with the proposed polyI:C/R848/PGE2 cocktail 
with a special focus on the interaction of resulting DCs with 
 CD8+ T-cells. We confirm previous data that TLR-P matured 
DCs exhibit a mature phenotype and robust migratory and 
cytokine-secreting abilities. Furthermore, CDCs and TLR-P 
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DCs are equally able to successfully prime antigen-specific 
 CD8+ T-cell responses against tumor-associated antigens. 
However, we show for the first time that  PGE2 might impair 
cross-presentation of protein antigens to  CD8+ T cells in 
human DCs in a dose-dependent fashion. Our data have 
implications for choosing the optimal DC maturation cock-
tail, which should be adapted to the type of antigen used in 
a cancer vaccine.
Material and methods
DC generation
PBMCs were obtained from anonymized, surplus leukocyte 
reduction filters from thrombocyte donations. DCs were gen-
erated as previously described [12]: monocytes were puri-
fied by CD14-MACS as recommended by the manufacturer 
(Miltenyi Biotec, Germany). Sorted cells were resuspended 
in CellGro DC medium (CellGenix, Freiburg, Germany) 
containing 1vol% HSA at a concentration of 1.5 × 106 cells/
ml and plated on tissue culture flask (Nunclon™ Delta, 
Thermo Fisher Scientific). For differentiation of monocytes 
into immature DCs (iDCs) IL-4 (1000 U/ml) and GM-CSF 
(1000 U/ml) were used for 5 days (both from CellGenix). 
Fresh medium and cytokines were added on days 2 and 4. 
On day 5, DC maturation was induced by addition of either 
TNFα (1000 U/ml) and IL-1ß (2000 U/ml) (cocktail 1) or 
R848 (3 μg/ml, Invivogen), Poly I:C (20 μg/ml. Sigma-
Aldrich), and  PGE2 (10 µg/ml, Sigma-Aldrich) (cocktail 
2). The main objective of this study was to compare the 
impact of these two protocols on DC maturation. In some 
selected experiments,  PGE2 was omitted or dose-modified 
to highlight the role of this substance in the TLR-cocktail. 
After 16–48 h maturation, viable mature DCs (mDCs) were 
harvested by putting on ice for 20 min, repeatedly rinsed 
with cold PBS) pooled if DCs from the same donor and 
condition were cultured in separate wells, counted, and ana-
lyzed for further assays (see below). General yield of mature 
DCs from the starting monocyte population in this assay 
was 51.4% (35.2–80.6) (median and range, data not shown). 
DCs for experiments on phenotype, migration, and cytokine 
secretion were matured for 48 h as in the index publication 
[19]. For T-cell experiments, a 16 h DC maturation period 
was strongly recommended in the original publications [20, 
21], and backed by our own data. Thus, for T-cell prim-
ing and cross-presentation experiments, a 16 h maturation 
period was chosen. Furthermore, to investigate the longevity 
and phenotype stability of matured DCs, we extended the 
culture period in some experiments for another 6 days. Dur-
ing this extended culture, DCs were washed and received 
only low-dose IL-4 and GM-CSF (250 U/ml) to avoid DC 
starvation but no further maturing agents.
For cross-presentation experiments,  CD141+ DCs served 
as positive controls. To enrich this very low frequency 
DC subpopulation, PBMCs from HLA-A02*01 donors 
were incubated with blood-derived dendritic cell antigen 
3 (BDCA-3) microbeads (Miltenyi Biotec) and positively 
enriched on LS-MACS columns according to the manufac-
turer’s instructions. Due to the scarcity of events, the posi-
tive fraction was only enumerated in Neubauer chambers.
Flow cytometry
Monocytes, iDCs (day 5), and mDCs (day 7) were stained 
for expression of CD14 (clone MϕP9, APC), C86 (clone 
2331 (FUN-1), FITC), CD80 (clone L307.4, PE), CD83 
(clone HB15e, PE), HLA-DR (clone G46-6, APC), and 
DC-SIGN (clone DCN46, APC) in some experiments. Dead 
and pre-apoptotic cells were excluded by addition of 7-ami-
noactinomycin (7-AAD). Since CD86 and HLA-DR are 
constitutively expressed on most monocytes and DCs, the 
increase in MFI of these markers was used to assess matu-
ration. For CD80 and CD83, the increase in frequency of 
positive cells was noted. Cytometer settings were optimized 
for mDCs, and the same settings were used on day 0 and 7 
(with an threshold adjustment for the higher auto-fluores-
cence on day 7) so that MFI-values could be compared. T 
cells were stained for CD3 (clone HIT3a, PE), CD4 (clone 
SK3, PerCp), CD8 (clone SK1, PerCp), CD62L (clone 
DREG-56, APC), CD45RA (cloneHI100, FITC), CD45RO 
(clone UCHL1, PE), CD137 (clone 4B4-1, APC), VLA-4 
(CD29 (clone TS2/16, FITC) / CD49d (clone 9F10, PE) het-
erodimer), IFNγ (clone B27, PE), TNFα (clone 64.011.111, 
APC), and the indicated MHC-multimers. All antibodies 
were obtained from BD (BD Biosciences, Heidelberg, Ger-
many). Customized MHC-multimers (APC) were purchased 
from Proimmune (Oxford, UK). Cells were stained using 
standard four-color or intracellular (BD Fix&Perm) proce-
dures and a minimum of 10,000 events (for MHC-multimer 
and IFNγ-analysis 100.000 events) were acquired on a FAC-
SCalibur (BD). Quality assurance of the flow cytometer 
included weekly calibration and internal quality controls 
as well as four monthly external round robin tests. Isotype 
controls for all colors were included in all measurements. 
Results were analyzed with CellQuest Pro (version 5.2.1, 
BD) or FlowJo (version 9.6, TreeStar, Ashland, Oregon, 
USA).
Migration assay
Migration assays were performed in 24-well Transwell 
plates carrying permeable polycarbonate filters of 5 µm pore 
size (Corning Life Sciences). mDC were washed thoroughly 
and suspended in CellGro media at  106/ml. The lower cham-
bers of the Transwell were filled with 600 µl of CellGro 
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containing 25 ng/ml of chemokine ligand (CCL-)19 and 
CCL21 each (both from PeproTech). 100 µl of the mDC 
were added into the upper chamber and allowed to migrate 
for 3 h in a 5%  CO2, humidified incubator at 37 °C. 500 µl 
aliquot of the cells that had migrated to the lower chamber 
was counted by flow cytometry for a fixed period of 300 s 
at a constant speed. Values are given as median counts of 
migrated cell with range.
Cytokine secretion
Cell culture supernatant (200 µl) was collected after cen-
trifugation from each well after 8, 16, and 48 h of maturation 
and stored at − 20 °C until analysis. Analytes were measured 
according to the manufacturers instructions on a MagPix 
device (Luminex, Oosterhout, The Netherlands) using the 
Human Magnetic Multiplex Kit (LHC6003M, Lifetechnolo-
gies, Darmstadt, Germany). The Luminex assay includes 
an internal calibration set, high and low validation samples 
and a 7-point curve for standard generation. Analytes not 
fulfilling these internal validations or showing no eleva-
tion above the baseline (iDCs before maturation) were not 
included into the analysis. IL-12p70 was measured addition-
ally in a 96-well ELISA (ThermoFischer, Langenselbold, 
Germany). Samples were prepared according to the manu-
facturer’s instructions and measured at 450 nm on a Genios 
plate reader and analyzed using Magellan Software (Tecan, 
Crailsheim, Germany).
T‑cell assays
For T-cell priming assays, we used a previously described 
protocol [20, 21]. In brief, naive  CD8+ T cells were isolated 
from the peripheral blood of healthy donors using a purifica-
tion of  CD8+ events, followed by depletion with CD45RO 
and CD57 microbeads on LD and LS columns (Miltenyi, 
Bergisch Gladbach, Germany). Isolated naive  CD8+ T cells 
were incubated with IL-7 overnight. The next day, T cells 
were washed and mixed with irradiated, differently matured 
autologous DCs, pulsed with either the heteroclitic HLA-
A02*01-restricted peptide Melan-A26-35L as a control or 
alternative peptides as indicated at 1 µg/ml. IL-21 (30 ng/
ml, Peprotech) was added to the co-culture on day 0 the 
next morning. IL-7 and IL-15 (5 ng/ml, Peprotech) were 
added on days 3, 5, and 7 and cells were harvested on day 
10, some of them after restimulation with the original pep-
tide. The Melan-A26-35L (ELAGIGIGLTV, NetMHC 4.0 
affinity 1738.18 nM), neuroligin-4, X-linked (NLGN4X) 
(NLDTLMTYV, affinity 8.89 nM), and tyrosine-protein 
phosphatase non-receptor (PTP) (KVFAGIPTV, affinity 
5.87 nM) peptides were purchased from jpt (Berlin, Ger-
many), the CMV-peptide NLVPMVATV was synthesized 
by the peptide facility of the Department of Immunology, 
University of Tübingen. Harvested T-cells on day 10 or 12 
were analyzed for phenotype (CD3, CD8, CD62L, CD45RA, 
VLA4), MHC-multimer- and TNFα/IFNγ-positivity. TCR 
avidity was determined by stimulating harvested day10-T-
cells with autologous monocytes loaded with peptide con-
centrations ranging from 1 µg/ml to 1 pg/ml at a 4:1 ratio for 
5 h and assaying for TNFα and IFNγ-production.
Two independent responder T-cell lines with specific-
ity for the HLA-A02*01-restrcted CMV-peptide NLVP-
MVATV were established by stimulating PBMCs from a 
CMV-seropositive healthy donor with 1 µg/ml peptide and 
stimulating αCD28-mAb at 1 µl/ml (Miltenyi Biotec, Ber-
gisch-Gladbach, Germany). After 24 h stimulation,  CD137+ 
cells were positively isolated by magnetic CD137-cell sort-
ing on MACS columns (Miltenyi Biotec) [22]. The positive 
fraction was expanded for 11–15 days with IL-21 (10 ng/
ml), IL-7, and IL-15 (each 5 ng/ml) in CellGro Medium 
(CellGenix, Freiburg, Germany) supplemented with 1% P/S, 
and 5% human serum. New medium and cytokines were 
supplemented every 2–3 days. After 9 days. T-cells were res-
timulated with peptide-pulsed, irradiated allogeneic feeder 
cells and aCD28 costimulatory mAbs. Specificity of the 
cell lines was measured by binding of the HLA-A02, CMV 
MHC-multimer (APC, Immundex, Copenhagen, Denmark) 
on  CD8+ T cells. Target value was more than 70% MHC-
multimer-positive T-cells after the end of culture. T-cells 
were used either freshly or were cryopreserved for later use.
Cross‑presentation assays
For cross-presentation experiments, different DC subtypes 
were differentiated with IL-4 and GM-CSF as indicated 
above. Freshly isolated  CD141+ (BDCA-3) DCs served as 
a positive control. On day 6, in half of the wells CMVpp65 
recombinant protein (10 µl/ml, Miltenyi Biotec) was added 
and DCs were subsequently matured for another 16 h as 
indicated above. In some experiments,  PGE2 was omitted 
from or titrated into the TLR-agonist cocktail. BDCA-3 DCs 
were matured with polyI:C (20 ng/ml). Negative controls 
contained unloaded DCs, T-cells without stimulation and in 
some experiments (when sufficient  CD141+ DCs were avail-
able) also  CD8+ T cells from a CMV-seronegative donor 
against protein-loaded  CD141+ DCs. After maturation, 
the other half of the wells were pulsed with the NLVPM-
VATV peptide (1 µg/ml) for 1 h. Afterwards, all DCs were 
washed, resuspended at a concentration of 5 × 105/ml and 
100 µl plated in a 96-well. 100 µl of the CMV-responder 
cell line (2 × 106/ml) were added in the presence of Brefel-
din (Sigma, Taufkirchen, Germany) and co-incubated for 
7 h at 37 °C, 5%  CO2 (DC:T ratio 1:4). Subsequently, cells 
were permeabilized and stained for IFNγ/TNFα as outlined 
above. Results were calculated as relative deviation from 
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the positive control  (CD141+ DCs = 100%) in the respective 
experiments.
Statistical analysis
Intergroup differences were assessed by nonparametric 
Mann–Whitney U test assuming unequal variances between 
groups. For comparison of multiple groups, the non-par-
ametric Kruskal–Wallis rang-sum test was used. For dif-
ferences within a group the two-tailed t test was applied. 
p < 0.05 was considered statistically significant.
Results
Effect of cytokine versus TLR‑agonist‑based 
cocktails on DC maturation marker expression
First, we analyzed the differential effects of the cytokine-
based (TNFα/IL-1ß) versus TLR-P cocktail (R848/polyI:C/
PGE2) on DC maturation marker expression. Both cock-
tails resulted in a significant upregulation of CD80, CD83, 
CD86, and HLA-DR on day7-mDCs compared to day7-iDCs 
(Fig. 1). However, the TLR-P-cocktail resulted in signifi-
cantly more  CD80+ and  CD83+ DCs (Fig. 1a+b) as well as 
higher expression of CD86 and HLA-DR (Fig. 1e+f). CD14 
expression was lower on cytokine matured than on iDCs or 
TLR-P-mDCs (Fig. 1g), but percentages of residual  CD14+ 
cells after maturation were not different between the three 
groups (Fig. 1c). In contrast, DC-SIGN (CD209) which was 
already high on day7-iDCs significantly declined on TLR-P-
matured DCs, but not on CDCs (Fig. 1d).
mDC life span, phenotype stability, and migration 
capacity
Next, we were interested to see whether the two maturation 
cocktails had different long-term effects on DCs in terms 
of cell number and phenotype stability. To analyze this we 
washed out all maturing agents on day 7 and extended DC 
culture for another 6 days in medium supplemented only 
with low dose IL-4 and GM-CSF with the intention to avoid 
DC starvation. Under these conditions, cell numbers gradu-
ally declined, after TLR-P maturation significantly faster 
than in cytokine-matured or immature DCs (Fig. 2a). CD86 
and CD80 expression remained fairly constant, whereas 
CD83 expression declined over time in both matured versus 
immature DCs (Fig. 2a).
Directed migration towards secondary lymphatic 
organs along a lymphokine gradient represents one of the 
first actions a DC has to complete after injection. Using a 
CCL19/21-dependent migration assay, we could show that 
TNFα/IL-1ß induced significantly enhanced migration 
compared to iDCs, however, the TLR-P cocktail further 
boosted migration by more than one log. When  PGE2 was 
omitted in the TLR-agonist cocktail, the number of actively 
migrating cells significantly diminished, indicating that 
migratory capabilities in DCs optimally develop in the pres-
ence of  PGE2 (Fig. 2b). Titration of  PGE2 in the maturation 
cocktail from 10 ng/ml to 10 µg/ml showed that already low 
 PGE2 doses of 10 ng/ml resulted in increases of migratory 
capacity whereas further augmentation of the  PGE2 dose 
had only moderate effects (Fig. 2c). Migrated DCs from the 
lower chamber displayed a more uniform activation marker 
expression, suggesting that only a subfraction of mature DCs 
is endowed with the capacity to migrate or that migration 
impacted expression levels (Fig. 2b, lower histograms).
DC cytokine secretion
Cytokine secretion of DCs followed a clear time-dependent 
pattern: while only few cytokines were produced 8 h after 
start of maturation, secretion generally peaked after 16 h, 
and then slowly declined afterwards (Fig. 2d). With the 
exception of MCP-1, TLR-P-matured DCs showed the high-
est cytokine release which was significant at 16 h for IL-6, 
IL-8, IL-10, and IL-12 (Table 1). The IL-12/IL-10 ratio was 
positive at 16 and 48 h (Table 1), the increase at 48 h was 
caused by a faster drop of IL-10 compared to IL-12 values.
Since the Luminex assay measures IL-12p35/p40, we addi-
tionally selectively assayed the biologically active IL-12p70 
by ELISA: IL-12p70 was only detectable in TLR-P-matured 
DCs, whereas no IL-12p70 could be detected in supernatants 
of iDCs or CDCs at any time (Table 1). Since IL-12p70 and 
IL-10 were measured in two different assay systems, we did 
not determine the IL-12p70/IL-10 ratio.
De novo priming of tumor‑antigen‑specific T‑cells
Many cancer patients do not harbor pre-existing T-cell 
responses against tumor-associated antigens. Thus, de 
novo T-cell priming is of pivotal importance for function-
ality of cancer vaccines. To test the differential ability of 
our DCs to prime T-cells, we established an in vitro prim-
ing assay, in which highly purified naïve  CD8+ T-cells 
are primed against peptide-loaded autologous DCs and 
subsequently expanded. As described in the original 
publication, LPS/IFNγ-matured DCs served as a positive 
control and all assays included the heteroclitic Melan-
A26-35L peptide, which usually gives high-frequency 
responses [20]. To represent also antigens with lower 
precursor frequencies, we chose the previously described, 
glioma-associated  NLGN4X131-139 and  PTP1347-1355 pep-
tides [23]. As shown in Fig. 3a (left graph), all three 
types of DCs induced high-frequency Melan-A26-35L 
responses, whereas the two glioma peptides resulted in 
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substantially lower, but detectable  CD8+ T-cell responses. 
No significant differences in terms of primed MHC-mul-
timer+ T-cells between differently matured DC popula-
tions could be detected. Likewise, TLR-P DCs tended to 
induce greater proliferation of T cells compared to CDCs 
(Fig. 3a right graph). In line with the known high pre-
cursor frequency of Melan-A26-35L reactive T-cells in the 
naïve compartment (approximately 0.1%, i.e. 1/103), all 
wells contained Melan-A26-35L specific T-cells, whereas 
for  NLGN4X131-139 and  PTP1347-1355 only a fraction of 
10–46% of wells contained positive cells (Fig. 3b), result-
ing in a minimal naïve precursor T-cell frequency of at 
least 1/1.2 × 106 for  NLGN4X131-139 and 1/2.04 × 106 for 
 PTP1347-1355. Due to limiting cells numbers, TCR avid-
ity of induced T-cells could only be assayed for Melan-
A-specific T-cells. To test this, harvested T-cells from 
day 10 were restimulated with autologous monocytes 
pulsed with titrated peptide dosages from µg- to pg-
ranges. We found no difference in the TNFα- or IFNγ-
cytokine responsiveness of T-cells primed by differently 
matured DC subgroups (Fig. 3c). The phenotype of the 
whole expanded T-cell pool on day 10 showed a trend for 
more effector T-cells with the TLR-matured DCs: start-
ing from a homogenous naïve T-cell population, CD62L 
and CD45RA were subsequently downregulated and most 
T-cells were in naïve-memory transition after 10 days of 
expansion under these conditions (Fig. 3d). Gating on 
the primed MHC-multimer+ T-cells, we found that the 
expression of the CD49d/CD29 heterodimer (VLA-4), 
which represents a key homing receptor for CNS tissues 
significantly differed between T-cells induced by differ-
ently matured DCs. VLA-4 expression was more abun-
dant on MHC-multimer+ than on MHC-multimer− T-cells 
and was higher after T-cell stimulation with TLR-matured 
DCs (Fig. 3e). In conclusion, all three DC populations 
were able to prime antigen-specific  CD8+ T-cells from 
antigens with low and intermediate precursor frequency. 
We were not able to detect significant differences regard-
ing frequency and TCR avidity of T-cells resulting from 
priming with the three DC subpopulations, however, on 
the phenotype level, TLR-matured DCs tended to induce 
more effector T-cells with higher VLA-4 expression.
Cross‑presenting capacity
Finally, we wanted to investigate whether the different DC 
maturation cocktails affect the ability of DCs to cross-pre-
sent phagocytosed material to  CD8+ T-cells. To this end, we 
incubated iDCs in the phagocytic stage with the full length 
CMVpp65 protein, and matured them afterwards using 
the different cocktails. The ability of these differentially 
matured DCs to stimulate CMVpp65-specific polyfunctional 
(TNFα+IFNγ+)  CD8+ T-cell responses was tested by co-
incubating them with three different responder T-cell popu-
lations: either two CMVpp65-specific T-cell lines generated 
in our own lab or a CMVpp65 clone (kindly provided by F. 
Falkenburg and I. Jedema, Leiden). HLA-A*02+ donors with 
a clearly detectable  CD8+CMV-MHC-multimer+ population 
were used to generate two T-cell lines with a final CMV 
specificity of > 75% (Fig. 4a).  CD141+ (BDCA-3) DCs iso-
lated from peripheral blood of HLA-A*02:01 donors were 
chosen as a positive control, as these DCs are considered to 
be the human APC population with most potent cross-pre-
senting and T-cell stimulating function [24]. Further positive 
controls included peptide loaded DCs and PMA/Ionomycin 
stimulated T-cells (not shown), negative controls unloaded 
DCs, unstimulated T cells as well as  CD8+ responder 
T-cells from CMV-seronegative donors (Fig. 4c). Unloaded 
DCs did not stimulate CMV-specific responses, ruling out 
endogenous expression of CMVpp65 antigen by our DCs. 
As illustrated in Fig. 4b+c,  CD141+ DCs most effectively 
cross-presented the CMVpp65 protein, yielding the highest 
frequency of  CD8+IFNγ+TNFα+ T-cells (these values were 
subsequently defined as 100%). As expected, peptide-loaded 
DCs tended to result in slightly higher cytokine production, 
cross-presenting CDCs also gave non-inferior results. In 
contrast, TLR-P DCs showed significantly lower frequen-
cies of  CD8+IFNγ+TNFα+ T-cells compared both to their 
CDC counterparts as well as their internal peptide controls 
(Fig. 4b+c). This effect was reproducible in all three T-cell 
responder populations. To pinpoint the effect of  PGE2 in that 
assay, we excluded  PGE2 from the TLR-P-cocktail. Omis-
sion of  PGE2 restored cross-presenting function of TLR-
matured DCs back to normal levels. Furthermore, titration of 
 PGE2 in the maturation cocktail from 10 ng/ml to 10 µg/ml 
demonstrated that this effect of  PGE2 was dose-dependent 
(Fig. 4d). These data indicate that  PGE2 specifically inhib-
its cross-presentation of protein antigen to  CD8+ T-cells in 
human TLR-matured DCs.
Since cross-presenting and migratory capacities seem to 
be inversely regulated by  PGE2, we superimposed these data. 
The resulting overlay graph (Fig. 4e) suggests that concen-
trations of  PGE2 in the range of 10–100 ng/ml might be an 
optimal dose window where migratory capacity is already 
upregulated yet cross-presenting function is not totally 
abrogated.
Fig. 1  Expression of DC surface maturation markers. DCs were 
either analyzed in an immature state on day 7 or after 48 h matura-
tion. For CD80 (a), CD83 (b), CD14 (c), and DC-SIGN (d) percent-
ages of marker positive cells were determined, for the constitutive 
markers CD86 (e), HLA-DR (f), and CD14 (g) the change in fluores-
cence intensity is displayed. Gating strategy is detailed in supplemen-
tary Fig.  1a. h Representative examples of day7-mDCs. N indicates 
the number of experiments, n.s. not significant, line and error bars 
represent medians and ranges
◂
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Fig. 2  Stability, migration, and cytokine secretion of differen-
tially matured DCs. a After harvesting on day +7, DCs were main-
tained, counted, and phenotyped for another 6 days. Gating strategy 
is detailed in supplementary Fig.  1a. Each symbol represents the 
median of n = 5 experiments, differences of slopes were calculated 
by linear regression. b Number of DCs migrating along a CCL19/21 
gradient in a transwell assay. Gating strategy for identifying DCs is 
detailed in supplementary Fig.  1b. Line and error bars represent 
medians and ranges, each symbol represents one experiment. Histo-
grams show representative examples of CD86 and CD83 expression 
on all vs. migrated DCs. c DCs were matured with titrating doses of 
 PGE2 and assayed for targeted migration as described above, medians 
with ranges. d Heat map of cytokine concentrations in supernatants 
after 8, 16 and 48 h of maturation. Data from n = 7, n = 3 and n = 10 
experiments, respectively were  log2-transformed
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Discussion
Manufacturing of DCs under GMP conditions for use as a 
clinical-grade cancer vaccine aims at generating a homog-
enous cell population fulfilling predefined specifications 
with a Th1-promoting profile. In vitro conditions shield the 
cells from potentially harmful factors in a cancer-bearing 
host, and the manufacturing process should be adapted to 
the type of antigen used in the vaccine, e.g. RNA-transfected 
DCs should not be matured with polyI:C as this might hin-
der protein translation [25]. TNFα and IL-1ß are frequently 
used as the basic cytokine combination to induce pathway 
committed DCs, which are pro-inflammatory and migratory 
but still have capacity to mature further in vivo [12], e.g. by 
preparation of the injection site with proinflammatory sub-
stances such as imiquimod [11]. Our phenotypic data, show-
ing that TLR-P DCs exhibit significantly higher maturation 
marker expression such as CD80 and CD83 than CDCs are 
in line with this and confirm previous reports that TLR-ago-
nists induce full maturation in myeloid DCs [18, 26]. This 
fully mature phenotype was associated with a faster decline 
of DC numbers after prolonged in vitro culture, which can 
be explained with the higher amount of IL-10 produced by 
TLR-P DCs. Endogenous IL-10 production in TLR-matured 
myeloid DCs was demonstrated to inhibit accumulation 
of anti-apoptotic Bcl-2, which limits DC longevity [27]. 
Although the phenotype of DCs seemed to be rather stable 
over time, we cannot exclude a possible dedifferentiation of 
DCs e.g. into macrophages especially under the influence of 
IL-10. Notably, with the exception of MCP-1, all analyzed 
cytokine levels were higher after TLR-P maturation, which 
reached significance for IL-6, IL-8, IL-10, and IL-12p35/40, 
however, the IL-12p35/40/IL-10 ratio remained always posi-
tive. As expected, IL-12p70 production was greatly enhanced 
after TLR-P maturation [15, 28, 29], whereas in CDCs and 
iDCs, IL-12p70 remained below the detection limit. Although 
 PGE2 is known to reduce IL-12p70 production in DCs via a 
cyclic adenosine monophosphate (cAMP-)dependent inhibi-
tion of the IL-12p40 subunit [30, 31], our TLR-P DCs still 
produced substantial amounts of IL-12p70, suggesting that 
the TLR-stimulus sufficiently compensates for the inhibitory 
 PGE2 effect. Furthermore, considering migration times of 
24 h from skin to the draining lymph node [32] and a rela-
tively preserved  IL12p70 production after 48 h, we postulate 
that TLR-P DCs injected after 16 h maturation will still be 
able to secrete active IL-12p70 at the DC:CD8+ interface in 
the lymph node.
In terms of de novo T-cell priming, CDCs and TLR-P 
DCs as well as the LPS/IFNγ DCs, which served as a posi-
tive control, were able to induce tumor-antigen-specific 
 CD8+ T-cells at similar frequencies with a trend for higher 
proliferation of T-cells in the TLR-P group. The assay 
worked for tumor-associated peptides with an intermedi-
ate (Melan-A) and low (NLGNX and PTP) T-cell precursor 
frequency within the naïve T-cell repertoire, although the 
excellent MHC-binding affinity of the two latter glioma pep-
tides (200–300 fold higher than for Melan-A26-35L, according 
to the NetMHC4.0 algorithm) might also have contributed 
to optimal T-cell priming. Although the presence of IL-12 
(which was secreted by our TLR-matured DCs) during 
priming can result in high avidity T cells [33], we could 
not observe differences in T-cell avidity after our priming 
Table 1  Cytokine secretion by 
DCs after maturation, median 
[ranges]
Unit TLR-P DCs CDCs
Luminex assay after 16 h maturation
IL-6 [pg/ml] 97,855
[57,990–98,716]
1395
[124–2881]
p = 0.0001
IL-8 [pg/ml] 384,553
[369,029–588,577]
20,977
[1930–42,566]
p = 0.0008
IL-10 [pg/ml] 1669
[1454–3038]
71
[35–109]
p = 0.053
IL-12p35/p40 [pg/ml] 10,237
[9707–11,416]
310
[166–933]
p = 0.004
IL-12p35/p40/IL-10 after 16 h Ratio 6.7
[3.4–6.8]
5.0
[4.7–8.6]
n.s
IL-12p35/p40/IL-10 after 48 h Ratio 58
[16–1731]
27
[6–1919]
n.s
ELISA assay
IL-12p70 after 8 h [pg/ml] 14.7
[13.3–16.2]
0
IL-12p70 after 16 h [pg/ml] 75.1
[70.1–80.1]
0
IL-12p70 after 48 h [pg/ml] 51.2
[26.7–75.7]
0
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assay with the caveat that this was an in vitro system only. 
An in vivo animal model has demonstrated that IL-12 defi-
cient mice can mount protective CTL responses, when DCs 
were licensed by CD4 T-cell help, suggesting that DCs are 
able to use IL-12-independent pathways to prime naïve T 
cells [34]. Overall, methodologies which have demonstrated 
a benefit for T-cell function after contact with TLR-matured 
DCs varied substantially, ranging from increased allospe-
cific proliferation of splenocytes [15, 35] to augmented 
IFNγ-production of TCR-transduced T-cells after cognate 
antigen contact [18], making a clear conclusion difficult. 
Watchmaker et al. reported that all DCs subtypes in their 
study were able to expand  CD8+ T cells, but only type-1 
polarized DCs induced Granzyme B and the peripheral tis-
sue chemokines CCR7 and CCL5 on  CD8+ T-cells. These 
findings are consistent with our data, showing similar fre-
quencies of MHC-multimer+  CD8+ T cells but subtle dif-
ferences in phenotype (effector T-cells) and integrin (VLA-
4) expression. Therefore, we hypothesize that TLR-P DCs 
might confer the functional advantage of higher VLA-4 
expression, which represents an important CNS-homing 
receptor, to primed  CD8+ T-cells. Notably, in vivo adminis-
tration of the TLR3-agonist, poly-ICLC also promoted VLA-
expression on vaccine reactive CTLs [36].
A central finding of our study is that cross-presentation 
of protein antigens to  CD8+ T-cell lines was diminished in 
TLR-P DCs, a process that was dose-dependent and required 
the presence of  PGE2 during maturation. Ahmadi et al. had 
reported that in murine DCs the presence of  PGE2 during 
differentiation and maturation resulted in a defective DC 
Fig. 3  T-cell priming capacity of differentially matured DCs. a 
Naïve  CD8+ T-cells were primed against the peptides Melan-A26-35L, 
 NLGN4X131-139, and  PTP1347-1355 using differentially matured DCs. 
Medians and ranges from n = 3 experiments are shown. Dot plots 
depict gating strategy and representative MHC-multimer stainings. 
b From the same experiments the percentage of wells assessed as 
 multimerpos (threshold > 0.1%) was calculated. c TCR avidity was 
determined by restimulating T-cells with titrating dosages of peptide. 
Values at 1 µg/ml were set as 100% and all other values normalized 
to that maximum. Medians of n = 4 experiments, gating strategy is 
detailed in supplementary Fig.  1c. d Harvested day10-CD8+-T-cells 
were phenotyped and categorized into  Tnaive,  TCM,  TEM, and  Teff sub-
sets. Pie charts show median values of n = 3 experiments, dot plots 
display gating strategy and representative examples. e Analysis of 
integrin VLA-4 expression on harvested day10-CD8+ T-cells depend-
ing on MHC-multimer positivity.  CD8+ T cells were identified as 
shown in supplementary Fig.  1c. Columns represent median values 
with ranges, n indicates the number of experiments
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phenotype ultimately leading to abortive  CD8+ activation. 
 PGE2 is a member of a group of eicosanoids with pleio-
tropic effects on immune cells which are both context and 
dose-dependent [37]. In immune cells,  PGE2 acts pre-
dominantly via the high-affinity  EP2- and the low-affinity 
 EP4-receptor [38]. In accordance with our data, trigger-
ing of the  EP4-receptor at concentrations > 50 nM usually 
results in IL-12 and IL-23 reduction [39]. To the best of our 
knowledge, the biochemical pathways of  PGE2 to interfere 
with antigen cross-presentation have not been described yet 
and require further mechanistic studies. It should be noted 
however, that we tested only soluble proteins for cross-pres-
entation. Larger, particulate antigen, e.g. bigger fragments 
of tumor lysate might be handled differently, as uptake and 
allocation to intracellular compartments of antigens of dis-
tinct size and consistency follows different pathways [40].
In contrast to these latter findings, the pivotal role of 
 PGE2 in augmenting DC migratory capabilities, mediated 
through activation of the CCR7 promotor via the p38/MAPK 
pathway, is well documented [7, 41, 42]. Although we and 
others have shown that  PGE2 strongly enhances the CCR7-
dependent in vitro migratory capacity in a dose-dependent 
way, in vivo this effect might be rapidly counteracted by 
CCR7-downregulation in CCL19-rich environments [43]. 
Indeed, imaging studies failed to demonstrate a benefit for 
accumulation of  PGE2-matured DCs in secondary lymphoid 
organs [43, 44], making it uncertain whether this in vitro 
effect will translate into a clinical benefit. One limitation of 
our study is that all our readout assays were separate in vitro 
experiments. With these alone, the resulting net effect 
in vivo is difficult to predict. Therefore, further preclinical 
in vivo models are needed to assess the effects of  PGE2 on 
migration, CTL priming, and cross-presentation of a DC-
based cancer vaccine.
Sustained  CD8+ effector T-cell responses, the aim of each 
cancer vaccine, require  CD4+ T-cell help [45, 46], ideally 
Fig. 4  Cross-presenting capabilities of differently matured DC sub-
sets. a Representative FACS plots of key steps in the generation of 
CMV responder cell lines. b Frequency of cytokine producing, 
CMV-specific responder  CD8+ T cells after stimulation with dif-
ferent DC subtypes and antigen sources. Results were normalized 
to the positive control (BDCA-3 DCs). Columns represent medi-
ans with ranges, n the number of experiments, n.s. non-significant. 
c Representative examples of polyfunctional T-cells (gated on 
 SSClowCD8+CMV-MHC-multimer+). d Frequency of cytokine pro-
ducing, CMV-specific responder  CD8+ T cells after stimulation with 
DCs matured under titrated  PGE2 dosages, lines and error bars indi-
cate medians and ranges, n the number of experiments. e Overlay of 
Fig.  2c and 4d. Gray area highlights a potentially preferable  PGE2 
concentration range
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from the same epitope, which can only be achieved when 
the antigen (synthetic long peptides or proteins) is processed 
intracellularly by DCs and the resulting peptide fragments 
are presented on both MHC class I and II molecules [47]. 
In contrast, for short peptides, loading on pre-activated 
DCs was the best way to induce protective antitumor CTL 
responses [48]. Therefore, as one possible conclusion from 
our study, for DCs intended to be loaded exogenously with 
short peptides the TLR-P combination might be the right 
choice for maturation as suggested by Boullard et al. and 
others [19, 25], since TLR-P DCs are fully mature, produce 
IL-12p70, successfully prime  CD8+VLA-4+ T cells, and 
show superior migratory capabilities. More caution is war-
ranted when the vaccine antigen requires intracellular pro-
cessing before presentation. In these cases, CDCs might be 
the better choice, as cross-presenting functions are preserved 
and yet these DCs express costimulatory markers, exhibit 
targeted migration, and successfully prime naïve  CD8+ T 
cells as well. Alternatively,  PGE2 in nanomolar concentra-
tions could improve migratory functions while leaving no 
significant impact on cross-presentation. Thus, our data 
highlight an important new aspect of how different agents 
during maturation can impact DC functionality.
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